TRANSMITTAL FORM  (to be used for all correspondence after initial in total Number of Pages in This Submission	Art Unit  Examiner Name  Attorney Docket Number  ENCLOSURES (Check all	Patent and Tillection of infi 10/562,843 December Garcia-Ro 1651 D.K. Ware	r 29, 2005 andenas et al.
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks The Commissioner is hereby authorize Deposit Account No. 02-1818.	Address	Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):  Information Disclosure Statement Transmittal Letter (2 pages); PTO 1449 Form (5 pages); Foreign/other documents (21); and return receipt postcard.
SIGNA Firm Name Bell, Boyd, & Lloyd LLP	TURE OF APPLICANT, ATTO	RNEY, C	OR AGENT
Printed name Robert M. Barrett			
Date December 10, 2007		Reg. No.	30,142

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

December 10, 2007

Ocemox

Shannon

Shannon O'Connor

the date shown below:

Typed or printed name

Signature



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Garcia-Rondenas et al.

Appl. No.:

10/562,842

Conf. No.:

5990

Filed:

2005-12-29

Title:

COMPOSITION FOR TREATING AND/OR PREVENTING DYSFUNCTIONS

ASSOCIATED WITH TYPE 2 DIABETES MELLITUS

Art Unit:

1651

Examiner:

D. K. Ware

Docket No.:

112701-696

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Sir:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited on the enclosed PTO-1449 form be made during the course of examination of the above-identified application for United States patent. Pursuant to 37 C.F.R. 1.98, copies of all foreign patent documents and non-patent documents can be found in the parent, application no. 10/562,842, filed on December 29, 2005.

## This Information Disclosure Statement is submitted:

- [] Within three months of filing of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; before the mailing date of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a Request for Continued Examination.
- [X] After the period specified above, but before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application and is accompanied by one of:
  - [X] Payment of the fee set forth in 37 CFR 1.17(p); or
  - [] The certification specified in 37 CFR 1.97(e) follows.
- [] After the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application and is accompanied by the fee set forth in 37 CFR 1.17(p) and the certification specified in 37 CFR 1.97(e) follows.

- [] The undersigned counsel for applicant(s) hereby certifies each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- [] The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
- [ ] A copy of a Search Report from a corresponding foreign patent application is enclosed.
- [ ] A check in the amount of \$180 to cover the required fee is enclosed.
- [X] The Commissioner is hereby authorized to charge the amount of \$180 to cover the required fee to Deposit Account No. 02-1818.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-1818.

Respectfully submitted,

BELL, BOYD & LLOYD LLP

BY

Robert M. Barrett Reg. No. 30,142 Customer No. 29157

Dated: December 10, 2007